FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155846302> ?p ?o ?g. }

• W2155846302 endingPage "1105" @default.
• W2155846302 startingPage "1099" @default.
• W2155846302 abstract "Therapeutic prostate-specific antigen (PSA) -targeted poxviral vaccines for prostate cancer have been well tolerated. PROSTVAC-VF treatment was evaluated for safety and for prolongation of progression-free survival (PFS) and overall survival (OS) in a randomized, controlled, and blinded phase II study.In total, 125 patients were randomly assigned in a multicenter trial of vaccination series. Eligible patients had minimally symptomatic castration-resistant metastatic prostate cancer (mCRPC). PROSTVAC-VF comprises two recombinant viral vectors, each encoding transgenes for PSA, and three immune costimulatory molecules (B7.1, ICAM-1, and LFA-3). Vaccinia-based vector was used for priming followed by six planned fowlpox-based vector boosts. Patients were allocated (2:1) to PROSTVAC-VF plus granulocyte-macrophage colony-stimulating factor or to control empty vectors plus saline injections.Eighty-two patients received PROSTVAC-VF and 40 received control vectors. Patient characteristics were similar in both groups. The primary end point was PFS, which was similar in the two groups (P = .6). However, at 3 years post study, PROSTVAC-VF patients had a better OS with 25 (30%) of 82 alive versus 7 (17%) of 40 controls, longer median survival by 8.5 months (25.1 v 16.6 months for controls), an estimated hazard ratio of 0.56 (95% CI, 0.37 to 0.85), and stratified log-rank P = .0061.PROSTVAC-VF immunotherapy was well tolerated and associated with a 44% reduction in the death rate and an 8.5-month improvement in median OS in men with mCRPC. These provocative data provide preliminary evidence of clinically meaningful benefit but need to be confirmed in a larger phase III study." @default.
• W2155846302 created "2016-06-24" @default.
• W2155846302 creator A5000904446 @default.
• W2155846302 creator A5027334479 @default.
• W2155846302 creator A5027453053 @default.
• W2155846302 creator A5031421101 @default.
• W2155846302 creator A5052111462 @default.
• W2155846302 creator A5054383262 @default.
• W2155846302 creator A5058583497 @default.
• W2155846302 creator A5059431397 @default.
• W2155846302 creator A5059931764 @default.
• W2155846302 creator A5068920213 @default.
• W2155846302 creator A5070669850 @default.
• W2155846302 creator A5070922234 @default.
• W2155846302 creator A5073536820 @default.
• W2155846302 creator A5090532560 @default.
• W2155846302 date "2010-03-01" @default.
• W2155846302 modified "2023-10-09" @default.
• W2155846302 title "Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer" @default.
• W2155846302 cites W2037968594 @default.
• W2155846302 cites W2067910064 @default.
• W2155846302 cites W2098574945 @default.
• W2155846302 cites W2098931866 @default.
• W2155846302 cites W2103090668 @default.
• W2155846302 cites W2127283640 @default.
• W2155846302 cites W2130227816 @default.
• W2155846302 cites W2135172646 @default.
• W2155846302 cites W2146934263 @default.
• W2155846302 cites W2149752186 @default.
• W2155846302 cites W2155020307 @default.
• W2155846302 cites W2155679349 @default.
• W2155846302 cites W2165542862 @default.
• W2155846302 cites W2537394222 @default.
• W2155846302 cites W97014008 @default.
• W2155846302 doi "https://doi.org/10.1200/jco.2009.25.0597" @default.
• W2155846302 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2834462" @default.
• W2155846302 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20100959" @default.
• W2155846302 hasPublicationYear "2010" @default.
• W2155846302 type Work @default.
• W2155846302 sameAs 2155846302 @default.
• W2155846302 citedByCount "878" @default.
• W2155846302 countsByYear W21558463022012 @default.
• W2155846302 countsByYear W21558463022013 @default.
• W2155846302 countsByYear W21558463022014 @default.
• W2155846302 countsByYear W21558463022015 @default.
• W2155846302 countsByYear W21558463022016 @default.
• W2155846302 countsByYear W21558463022017 @default.
• W2155846302 countsByYear W21558463022018 @default.
• W2155846302 countsByYear W21558463022019 @default.
• W2155846302 countsByYear W21558463022020 @default.
• W2155846302 countsByYear W21558463022021 @default.
• W2155846302 countsByYear W21558463022022 @default.
• W2155846302 countsByYear W21558463022023 @default.
• W2155846302 crossrefType "journal-article" @default.
• W2155846302 hasAuthorship W2155846302A5000904446 @default.
• W2155846302 hasAuthorship W2155846302A5027334479 @default.
• W2155846302 hasAuthorship W2155846302A5027453053 @default.
• W2155846302 hasAuthorship W2155846302A5031421101 @default.
• W2155846302 hasAuthorship W2155846302A5052111462 @default.
• W2155846302 hasAuthorship W2155846302A5054383262 @default.
• W2155846302 hasAuthorship W2155846302A5058583497 @default.
• W2155846302 hasAuthorship W2155846302A5059431397 @default.
• W2155846302 hasAuthorship W2155846302A5059931764 @default.
• W2155846302 hasAuthorship W2155846302A5068920213 @default.
• W2155846302 hasAuthorship W2155846302A5070669850 @default.
• W2155846302 hasAuthorship W2155846302A5070922234 @default.
• W2155846302 hasAuthorship W2155846302A5073536820 @default.
• W2155846302 hasAuthorship W2155846302A5090532560 @default.
• W2155846302 hasBestOaLocation W21558463022 @default.
• W2155846302 hasConcept C121608353 @default.
• W2155846302 hasConcept C126322002 @default.
• W2155846302 hasConcept C141071460 @default.
• W2155846302 hasConcept C143998085 @default.
• W2155846302 hasConcept C168563851 @default.
• W2155846302 hasConcept C203092338 @default.
• W2155846302 hasConcept C207103383 @default.
• W2155846302 hasConcept C2777701055 @default.
• W2155846302 hasConcept C2780192828 @default.
• W2155846302 hasConcept C44249647 @default.
• W2155846302 hasConcept C71924100 @default.
• W2155846302 hasConceptScore W2155846302C121608353 @default.
• W2155846302 hasConceptScore W2155846302C126322002 @default.
• W2155846302 hasConceptScore W2155846302C141071460 @default.
• W2155846302 hasConceptScore W2155846302C143998085 @default.
• W2155846302 hasConceptScore W2155846302C168563851 @default.
• W2155846302 hasConceptScore W2155846302C203092338 @default.
• W2155846302 hasConceptScore W2155846302C207103383 @default.
• W2155846302 hasConceptScore W2155846302C2777701055 @default.
• W2155846302 hasConceptScore W2155846302C2780192828 @default.
• W2155846302 hasConceptScore W2155846302C44249647 @default.
• W2155846302 hasConceptScore W2155846302C71924100 @default.
• W2155846302 hasIssue "7" @default.
• W2155846302 hasLocation W21558463021 @default.
• W2155846302 hasLocation W21558463022 @default.
• W2155846302 hasLocation W21558463023 @default.
• W2155846302 hasLocation W21558463024 @default.
• W2155846302 hasOpenAccess W2155846302 @default.
• W2155846302 hasPrimaryLocation W21558463021 @default.

• next